CENTOCOR, INC.

ADVANCING THE SCIENCE OF DERMATOLOGY

PHARMACEUTICAL PREPARATIONS FOR DERMATOLOGICAL USE;

AGGRESTAT

medical diagnostic instruments, namely platelet aggregometers;

AVAKINE

pharmaceutical compositions for treatment of autoimmune diseases and disorders;

CA 125

radioimmunoassays for ovarian cancer;

CA 125

diagnostic tumor marker immunoassays containing antibodies for detecting overian cancer for clinical or medical laboratory use;diagnostic tumor marker immunoassays containing antibodies for detecting overian cancer for scientific or research use;CA;

CA 15-3

diagnostic tumor marker immunoassays containing antibodies for detecting gastrointinal cancer for clinical or medical laboratory use;CA15 3;diagnostic tumor marker immunoassays containing antibodies for detecting gastrointestinal cancer for scientific or research use;CA;

CA 19-9

radioimmunoassays for gastrointestinal cancer;19-9;

CA 19-9

diagnostic tumor marker immunoassays containing antibodies for detecting gastrointestinal cancer for clinical or medical laboratory use;diagnostic tumor marker immunoassays containing antibodies for detecting gastrointestinal cancer for scientific or research use;CA;

CAPISCINT

PHARMACEUTICALS, NAMELY, IMMUNODIAGNOSTIC AGENTS USED IN THE DETECTION OF CARDIOVASCULAR DISEASE;

CENTARA

immunotherapeutic agents for the treatment of autoimmune disease;

CENTNF

anti-TNF monoclonal antibodies for the pharmaceutical treatment of human diseases;

CENTORX

IMMUNOTHERAPEUTIC AGENTS FOR BLOOD CLOTS;

CENTORX

IN THE STATEMENT, COLUMN 1, LINE 1, MASSACHUSETTS SHOULD BE DELETED AND PENNSYLVANIA SHOULD BE INSERTED.;PHARMACEUTICALS, NAMELY, IMMUNO-THERAPEUTIC AGENTS USED IN THE TREATMENT OF BLOOD CLOTS;

CENTOXIN

IMMUNOTHERAPEUTIC AGENTS FOR BACTERIAL INFECTIONS;

EGEA

biological and chemical materials, namely, products derived from living sources in the nature of vaccines, blood and blood derivatives, monoclonal antibodies, and products derived from recombinant DNA, for use in therapeutics and diagnostics;biological and chemical materials, namely, oligoneucleotides, polynucleotides, peptides and polypeptides for use in scientific and medical research;biological and chemical research in the nature of synthesis of biological and chemical materials; product design for others in the field of synthesis of biological and chemical materials;

FIBRISCINT

IMMUNODIAGNOSTIC AGENTS FOR BLOOD CLOTS;

HA-1A

immunotherapeutic agents for bacterial infections;

MAKE EVERYDAY COUNT

pharmaceutical for treatment of autoimmune diseases and disorders;

MAMMOCOR

diagnostic reagents for clinical or medical laboratory use;

MIMETIBODY

pharmaceutical composition, namely, small peptide or protein fused with an antibody or antibody fragment for use in the treatment of cancer, renal failure, anemia, cardiovascular disease, metabolic disease, immune and inflammatory diseases, and infectious diseases;

MYOSCINT

KITS CONTAINING COMPONENTS FOR PRODUCING A RADIOLABELED MONOCLONAL ANTIBODY OR A RADIOLABELED FRAGMENT OF AN ANTIBODY FOR INTRAVENOUS USE;

P-GLYCO MAB

REAGENTS FOR DETERMINING DRUG RESISTANCE FOR MEDICAL DIAGNOSTIC USE;MAB;

P-GLYCOCHEK

TEST KITS CONTAINING REAGENTS FOR DETERMINING DRUG RESISTANCE FOR MEDICAL DIAGNOSTIC USE;POLYGLYCO CHECK;

REMICADE

pharmaceutical preparations for the treatment of autoimmune diseases and autoimmune disorders;Color is not claimed as a feature of the mark.;The stippling in the drawing is for shading purposes.;

REMICARE

Printed materials, namely, pamphlets, newsletters, brochures and periodicals relating to the promotion of pharmaceuticals;

RRED

automated cellular analysis system, comprising a computer controlled microscope for the analysis of biological specimens prepared with reagents;

SURVIVE AND SUCCEED

consumer education program related to rheumatoid arthritis;